China's diabetes devices market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, with a CAGR of 8.11%. Growth is driven by rising diabetes prevalence (118 million patients), aging population, government healthcare reforms, and technological advancements in glucose monitoring and insulin delivery systems. Key challenges include cost sensitivity and uneven reimbursement coverage across regions.

Viking Therapeutics is a biotech company developing weight loss drugs in the GLP-1 class, with injectable VK2735 in phase 3 trials and an oral candidate entering phase 3 in Q3 2026. The obesity drug market is projected to reach $100 billion by decade's end, currently dominated by Eli Lilly and Novo Nordisk. While Viking stock has shown volatility and room to run from current levels, the article cautions that a single stock is unlikely to make investors millionaires, but could be a valuable addition to a diversified portfolio.

Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk's 39% share, driven by superior clinical results and manufacturing investments. The company's tirzepatide-based drugs (Zepbound and Mounjaro) generated over $11 billion in recent quarterly revenue. However, the author predicts that retatrutide, a triple-pathway hormone agonist candidate showing 28% body weight reduction in trials, could further cement Lilly's market leadership by offering superior efficacy compared to current treatments.

Eli Lilly has significantly outperformed Novo Nordisk over the past three years, with Eli Lilly reaching a $1 trillion market cap while Novo Nordisk's value has declined. Eli Lilly's weight-loss drug Zepbound proved more effective than Novo Nordisk's Wegovy in clinical trials, and Eli Lilly has a stronger pipeline with candidates like retatrutide showing impressive results. While Eli Lilly maintains its market leadership, Novo Nordisk's stock may offer value at current valuations with potential upside from its deep pipeline.

GoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's oral GLP-1 medication Foundayo and Zepbound.

Novo Nordisk announced a strategic partnership with OpenAI to accelerate drug discovery and development using advanced AI tools. The collaboration will analyze complex datasets, identify drug candidates, and streamline clinical transitions while reducing development timelines. Beyond research, AI will be applied to manufacturing, supply chain, and operations, with pilot programs rolling out across divisions by end of 2026. The partnership includes data protection safeguards and workforce upskilling initiatives.

The alpha thalassemia market is expected to expand significantly through 2036, driven by rising prevalence and advancements in diagnostics and gene therapies. Key players Agios Pharmaceuticals and Novo Nordisk are leading development efforts with emerging drugs like PYRUKYND and etavopivat progressing through clinical trials, though no gene therapies are currently approved for the condition.

Eli Lilly's Mounjaro is losing market share in India as cheaper generic alternatives, particularly semaglutide copies, gain traction. Mounjaro sales dropped from $14.6 million to $12.3 million between February and March, with its market share falling from 71% to 64%. However, Lilly's competitive position was bolstered by FDA approval of Foundayo, a once-daily oral GLP-1 pill for weight loss and obesity.

Three major companies across nuclear, pharma, and travel sectors announced share buyback programs. Constellation Energy's $5 billion buyback (5% of market cap) signals confidence despite 20% YTD decline and regulatory headwinds. Novo Nordisk's 15 billion Danish kroner buyback (under 1% of market cap) raises confidence concerns given its 75% decline from peak and market share losses to competitors. Carnival's $2.5 billion buyback (7% of market cap) demonstrates strong confidence backed by record Q1 results and robust future bookings.

Eli Lilly received FDA approval for Foundayo (orforglipron), its GLP-1 pill for weight loss, launching April 6. The drug has advantages over Novo Nordisk's Wegovy pill, including no food or water restrictions. Eli Lilly's pipeline also includes retatrutide, a triple-hormone receptor agonist in phase 3 trials showing superior weight loss results (28.7% vs Novo's 23%), positioning Lilly to dominate the obesity drug market.

Novo Nordisk announced a new subscription model for Wegovy offering 3, 6, or 12-month prescriptions at discounted prices to expand market reach in the weight-loss drug space. Despite losing market leadership to Eli Lilly, the company's pricing strategy could help penetrate the underpenetrated obesity market, where only 12% of Americans currently use GLP-1 drugs despite 40-70% obesity rates. Novo Nordisk stock trades at an attractive valuation of 11x forward earnings compared to healthcare average of 17.3x.

The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.